1.0 Background - ANZCTR

(CYP3A4 and beta-adrenergic blocking agents), medications used to treat pulmonary arterial hypertension, and other phosphodiesterase type 5 inhibitors. All participants must be able to understand the study information . sheet, and. provide informed consent of their desire to participate in the research study. 4.2 Withdrawal criteria ................
................